Patients with COVID-19 have increased Th1 and Th2 response two weeks after the onset of infection, and present with extended lung damage and risk of death when elevated levels of Interleukin-6 (IL-6) are detected (Ruan et al., 2020). The gene discussed is IL6; the disease is COVID-19.